The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.

The present disclosure relates to a process for separation of enantiomers of the amino acid from a racemic mixture. The process comprises electrolyzing the first electrolyte having 1 molar solution of lithium perchlorate and 0.01 molar solution of racemic mixture of amino acid in an electrochemical cell containing a working electrode having polycrystalline metal surface configured to adsorb L-enantiomer of amino acid using a saw-tooth current. Further, the polarity of the saw-tooth current is reversed to de-adsorb the L-enantiomer of amino acid from the working electrode into the second electrolyte re-filled in the cell. The process of the present disclosure to separate enantiomer of amino acid from a racemic mixture is simple and economical.

The present disclosure relates to a process for separation of enantiomers of the amino acid from a racemic mixture. The process comprises electrolyzing the first electrolyte having 1 molar solution of lithium perchlorate and 0.01 molar solution of racemic mixture of amino acid in an electrochemical cell containing a working electrode having polycrystalline metal surface configured to adsorb L-enantiomer of amino acid using a saw-tooth current. Further, the polarity of the saw-tooth current is reversed to de-adsorb the L-enantiomer of amino acid from the working electrode into the second electrolyte re-filled in the cell. The process of the present disclosure to separate enantiomer of amino acid from a racemic mixture is simple and economical.

The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.

The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.

The present invention relates to chiral auxiliaries and the syntheses thereof and uses thereof.

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

The present invention relates to kinetic resolution of racemic -hydroxyl ester via asymmetric catalytic hydrogenation and an application thereof. In the presence of chiral spiro pyridyl phosphine ligand Iridium catalyst and base, racemic -hydroxyl esters were subjected to asymmetric catalytic hydrogenation to obtain extent optical purity chiral -hydroxyl esters and corresponding 1,5-diols. An optically active chiral -hydroxyl ester and 1,5-diols can be obtained at very high enantioselectivity and yield with relatively low usage of catalyst. The chiral -hydroxyl ester and 1,5-diols obtained by using the method can be used as a critical raw material for asymmetric synthesis of chiral drugs (R)-lisofylline and natural drugs (+)-civet, ()-indolizidine 167B and ()-coniine.

The present invention relates to kinetic resolution of racemic -hydroxyl ester via asymmetric catalytic hydrogenation and an application thereof. In the presence of chiral spiro pyridyl phosphine ligand Iridium catalyst and base, racemic -hydroxyl esters were subjected to asymmetric catalytic hydrogenation to obtain extent optical purity chiral -hydroxyl esters and corresponding 1,5-diols. An optically active chiral -hydroxyl ester and 1,5-diols can be obtained at very high enantioselectivity and yield with relatively low usage of catalyst. The chiral -hydroxyl ester and 1,5-diols obtained by using the method can be used as a critical raw material for asymmetric synthesis of chiral drugs (R)-lisofylline and natural drugs (+)-civet, ()-indolizidine 167B and ()-coniine.